Selected article for: "clinical stage and large number"

Author: Cao, Wei; Liu, Xiaosheng; Bai, Tao; Fan, Hongwei; Hong, Ke; Song, Hui; Han, Yang; Lin, Ling; Ruan, Lianguo; Li, Taisheng
Title: High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
  • Document date: 2020_3_21
  • ID: u3gmpklc_22
    Snippet: IVIg is a blood product containing polyclonal immunoglobulin G isolated and pooled from healthy donors, and it has been used for over 30 years. As a complex preparation, it contains a large number of bioactive moieties, and the entirety of its effects is not yet fully understood. IVIg of higher dose has been a choice of immunomodulatory therapy for autoimmune or inflammatory disease and for prophylaxis and treatment of severe infections, especial.....
    Document: IVIg is a blood product containing polyclonal immunoglobulin G isolated and pooled from healthy donors, and it has been used for over 30 years. As a complex preparation, it contains a large number of bioactive moieties, and the entirety of its effects is not yet fully understood. IVIg of higher dose has been a choice of immunomodulatory therapy for autoimmune or inflammatory disease and for prophylaxis and treatment of severe infections, especially in immunocompromised patients [11, 12] . Several theories have been proposed to explain its potential immunomodulatory mechanisms, including Fc-mediated and Fab-mediated approaches [13, 14] . In previous studies of SARS and Middle East respiratory syndrome (MERS), IVIg therapy has exhibited various clinical benefits with good tolerance [15] [16] [17] . Considering its efficacy in improving passive immunity and modulating immune inflammation and the overall safety profile, high-dose IVIg could be considered a promising option at the early stage of clinical deterioration of patents with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • blood product and healthy donor: 1
    • blood product and high dose: 1
    • blood product and high dose IVIg: 1
    • clinical benefit and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical benefit and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • clinical benefit and high dose IVIg: 1
    • clinical deterioration and early stage: 1, 2, 3, 4, 5, 6, 7, 8
    • clinical deterioration and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • clinical deterioration and high dose IVIg: 1, 2, 3
    • early stage and fully understand: 1, 2
    • early stage and healthy donor: 1
    • early stage and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • early stage and high dose IVIg: 1, 2, 3, 4
    • fully understand and high dose: 1